| Imaging in diagnosis, outcome prediction and monitoring of large vessel vasculitis: a systematic literature review and meta-analysis informing the EULAR recommendations |
40 |
| Definitions and reliability assessment of elementary ultrasound lesions in giant cell arteritis: a study from the OMERACT Large Vessel Vasculitis Ultrasound Working Group |
27 |
| Systemic sclerosis: state of the art on clinical practice guidelines |
25 |
| Distinguishing rheumatoid arthritis from psoriatic arthritis |
17 |
| MRI for diagnosis of axial spondyloarthritis: major advance with critical limitations 'Not everything that glisters is gold (standard)' |
17 |
| Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study |
17 |
| Systemic lupus erythematosus: state of the art on clinical practice guidelines |
15 |
| Era of biosimilars in rheumatology: reshaping the healthcare environment |
15 |
| Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy |
14 |
| Window of opportunity in rheumatoid arthritis - definitions and supporting evidence: from old to new perspectives |
13 |
| Management of thrombotic and obstetric antiphospholipid syndrome: a systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults |
13 |
| Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations |
13 |
| Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study |
13 |
| Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials |
12 |
| Cartilage-gut-microbiome axis: a new paradigm for novel therapeutic opportunities in osteoarthritis |
12 |
| Failure to reach uric acid target of < 0.36 mmol/L in hyperuricaemia of gout is associated with elevated total and cardiovascular mortality |
12 |
| Diagnostic accuracy of inflammatory back pain for axial spondyloarthritis in rheumatological care |
11 |
| 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis |
11 |
| Osteoporosis in psoriatic arthritis: a cross-sectional study of an outpatient clinic population |
11 |
| Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD |
11 |
| Antiphospholipid syndrome: state of the art on clinical practice guidelines |
11 |
| MR signal intensity: staying on the bright side in MR image interpretation |
10 |
| Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis |
10 |
| Efficacy and safety of non-pharmacological, pharmacological and surgical treatment for hand osteoarthritis: a systematic literature review informing the 2018 update of the EULAR recommendations for the management of hand osteoarthritis |
10 |
| Bromodomain protein inhibition: a novel therapeutic strategy in rheumatic diseases |
10 |
| Transition phase towards psoriatic arthritis: clinical and ultrasonographic characterisation of psoriatic arthralgia |
10 |
| Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial |
9 |
| Efficacy, safety and immunogenicity of GP an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study |
9 |
| Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis |
9 |
| Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study |
9 |
| Polymyalgia rheumatica-like syndrome from checkpoint inhibitor therapy: case series and systematic review of the literature |
9 |
| Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden - a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs |
9 |
| Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the AGREE study |
9 |
| Identification of sarilumab pharmacodynamic and predictive markers in patients with inadequate response to TNF inhibition: a biomarker substudy of the phase 3 TARGET study |
9 |
| Peripheral disease contributes significantly to the level of disease activity in axial spondyloarthritis |
9 |
| Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs |
9 |
| Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis |
9 |
| Effects of exercise and physical activity promotion: meta-analysis informing the 2018 EULAR recommendations for physical activity in people with rheumatoid arthritis, spondyloarthritis and hip/knee osteoarthritis |
9 |
| Characteristics and burden of disease in patients with radiographic and non-radiographic axial Spondyloarthritis: a comparison by systematic literature review and meta-analysis |
9 |
| Ehlers-Danlos syndromes: state of the art on clinical practice guidelines |
8 |
| Rare diseases under different levels of economic analysis: current activities, challenges and perspectives |
8 |
| Long-term persistence of TNF-inhibitor treatment in patients with psoriatic arthritis. Data from the British Society for Rheumatology Biologics Register |
8 |
| Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies |
8 |
| Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond |
8 |
| Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study |
8 |
| Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features |
7 |
| Clinical characteristics and patient-reported outcomes in patients with inadequately controlled rheumatoid arthritis despite ongoing treatment |
7 |
| Neural networks for automatic scoring of arthritis disease activity on ultrasound images |
7 |
| Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial |
7 |
| Methods to improve medication adherence in patients with chronic inflammatory rheumatic diseases: a systematic literature review |
7 |
